Ignite Creation Date:
2025-12-25 @ 12:06 AM
Ignite Modification Date:
2026-02-20 @ 4:44 PM
Study NCT ID:
NCT00297258
Status:
COMPLETED
Last Update Posted:
2016-02-03
First Post:
2006-02-24
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
Sponsor:
GlaxoSmithKline
Organization:
Study Overview
Official Title:
Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: